Recro Pharma Inc (REPH): Are Hedge Funds Right About This Stock?
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its......(read more)
Posts Tagged ‘NASDAQ:REPH’
Did Hedge Funds Drop The Ball On Recro Pharma Inc (REPH)?
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. The S&......(read more)
Recro Pharma, Inc. (REPH): Here are Midwood Capital Management’s Thoughts On The Pharmaceutical Company
Midwood Capital Management explained recent Recro Pharma (NASDAQ:REPH) stock price fluctuations in its Q1 2019 Investor Letter. If you are interested......(read more)
Here is What Artko Capital Thinks About Recro Pharma, Inc. (REPH)
Artko Capital recently released its Q1 2019 Investor Letter, which you can track down here. In it, the fund reported its quarterly return of 10.3% and......(read more)
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Recro Pharma Inc. (NASDAQ:REPH): Kevin Kotler’s Broadfin Capital filed an amended 13D. You can check out Broadfin Capital’s latest holdings......(read more)
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Recro Pharma Inc. (NASDAQ:REPH): Kevin Kotler’s Broadfin Capital filed an amended 13D. You can check out Broadfin Capital’s latest holdings......(read more)
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Recro Pharma Inc. (NASDAQ:REPH): Kevin Kotler’s Broadfin Capital filed an amended 13D. You can check out Broadfin Capital’s latest holdings......(read more)
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Recro Pharma Inc. (NASDAQ:REPH): Kevin Kotler’s Broadfin Capital filed an amended 13D. You can check out Broadfin Capital’s latest holdings......(read more)
Recro Pharma Inc (REPH): Here’s What’s Next
Recro Pharma Inc (NASDAQ:REPH) is one of the week’s runners in biotech so far. The company just put out data from a late stage trial and gained......(read more)
Recro Pharma Inc. (REPH): Largest Shareholder Broadfin Capital Buys Even More Shares
An amended 13D filing with the Securities and Exchange Commission showed that Kevin Kotler‘s Broadfin Capital has acquired more shares of Recro......(read more)
A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)’s Topline Triumph
Recro Pharma Inc (NASDAQ:REPH) is up more than 27% on Wednesday after announcing data from its lead acute pain trial. The company has developed an IV......(read more)
Jason Karp Takes Long Position In This Stock, Up By 480% This Year
Jason Karp’s Tourbillon Capital Partners recently filed a 13G form with the SEC indicating that it now owns 7.0% of the common shares of Recro Pharma......(read more)
Healthcare Expert Kevin Kotler Boosts His Stake In Recro Pharma Inc. (REPH)
Kevin Kotler’s Broadfin Capital has filed a 13D with the Securities and Exchange Commission regarding its stake in Recro Pharma Inc. (NASDAQ:REPH).......(read more)
Servicesource International Inc (SREV), Recro Pharma Inc (REPH): Altai Capital And Broadfin Capital’s Latest Moves
According to a recent filing with the Securities and Exchange Commission, Altai Capital, run by Rishi Bajaj, Toby Symonds and Steve Tesoriere, has increased......(read more)
Sabby Management Adds Bioline RX Ltd (BLRX) & Recro Pharma Inc (REPH) to Its Equity Portfolio
In a couple of new filings with the SEC, Hal Mintz‘s Sabby Management disclosed adding two companies to its equity portfolio: Bioline RX Ltd (NASDAQ......(read more)
Broadfin Capital Initiates Stake in Newly Public Recro Pharma Inc (REPH)
Broadfin Capital, managed by Kevin Kotler, has disclosed in a new filing with the U.S. Securities and Exchange Commission holding shares of Recro Pharma......(read more)
